CN101437802A - 17-氧基麦克菌素衍生物及其在癌症和/或b-细胞恶性肿瘤的治疗中的用途 - Google Patents

17-氧基麦克菌素衍生物及其在癌症和/或b-细胞恶性肿瘤的治疗中的用途 Download PDF

Info

Publication number
CN101437802A
CN101437802A CNA2007800165888A CN200780016588A CN101437802A CN 101437802 A CN101437802 A CN 101437802A CN A2007800165888 A CNA2007800165888 A CN A2007800165888A CN 200780016588 A CN200780016588 A CN 200780016588A CN 101437802 A CN101437802 A CN 101437802A
Authority
CN
China
Prior art keywords
represent
oxymacbecin
analogue
compound
mike
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800165888A
Other languages
English (en)
Chinese (zh)
Inventor
C·马丁
M·张
S·盖瑟
N·科茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotica Technology Ltd
Original Assignee
Biotica Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotica Technology Ltd filed Critical Biotica Technology Ltd
Publication of CN101437802A publication Critical patent/CN101437802A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
CNA2007800165888A 2006-05-09 2007-05-09 17-氧基麦克菌素衍生物及其在癌症和/或b-细胞恶性肿瘤的治疗中的用途 Pending CN101437802A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0609117.7A GB0609117D0 (en) 2006-05-09 2006-05-09 Novel compounds
GB0609117.7 2006-05-09

Publications (1)

Publication Number Publication Date
CN101437802A true CN101437802A (zh) 2009-05-20

Family

ID=36637122

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800165888A Pending CN101437802A (zh) 2006-05-09 2007-05-09 17-氧基麦克菌素衍生物及其在癌症和/或b-细胞恶性肿瘤的治疗中的用途

Country Status (11)

Country Link
US (1) US20100068203A1 (enExample)
EP (1) EP1940798A1 (enExample)
JP (1) JP2009536934A (enExample)
KR (1) KR20090005377A (enExample)
CN (1) CN101437802A (enExample)
AU (1) AU2007247119A1 (enExample)
BR (1) BRPI0711092A2 (enExample)
CA (1) CA2651557A1 (enExample)
GB (1) GB0609117D0 (enExample)
MX (1) MX2008014279A (enExample)
WO (1) WO2007128827A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110160175A1 (en) * 2006-09-11 2011-06-30 Christine Martin 18,21-Didesoxymacbecin Derivatives for the Treatment of Cancer
US9967590B2 (en) 2008-04-10 2018-05-08 Qualcomm Incorporated Rate-distortion defined interpolation for video coding based on fixed filter or adaptive filter
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
CN110999828A (zh) * 2019-12-19 2020-04-14 上海海洋大学 改变鱼类体色分布模式的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2146668A1 (en) * 1992-10-14 1994-04-28 Luke Whitesell Tumoricidal activity of benzoquinonoid ansamycins against prostate cancer and primitive neural malignancies
EP0828418A4 (en) * 1995-05-02 2000-03-29 Univ California INDUCTION OF THERMOTOLERANCE WITH BENZOCHINOIDS ANSAMYCINES

Also Published As

Publication number Publication date
GB0609117D0 (en) 2006-06-21
WO2007128827A8 (en) 2008-01-03
US20100068203A1 (en) 2010-03-18
MX2008014279A (es) 2008-11-26
CA2651557A1 (en) 2007-11-15
EP1940798A1 (en) 2008-07-09
JP2009536934A (ja) 2009-10-22
BRPI0711092A2 (pt) 2011-08-23
WO2007128827A1 (en) 2007-11-15
KR20090005377A (ko) 2009-01-13
AU2007247119A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
CN101437802A (zh) 17-氧基麦克菌素衍生物及其在癌症和/或b-细胞恶性肿瘤的治疗中的用途
US20090209494A1 (en) 21-deoxymacbecin analogues useful as antitumor agents
US20090253667A1 (en) 18 ,21-Didesoxymacbecin Derivatives for the Treatment of Cancer
US20110160175A1 (en) 18,21-Didesoxymacbecin Derivatives for the Treatment of Cancer
EP1973883B1 (en) Novel compounds and methods for their production
US20090117127A1 (en) Novel Compounds and Methods for Their Production
US20090209507A1 (en) 15-O-Desmethylmacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies
CN101460465A (zh) 用于癌症治疗的18,21-双脱氧麦克菌素衍生物
US20110091452A1 (en) 4,5-Dihydromacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies
US20090298804A1 (en) Novel Compounds and Methods for Their Production
KR20090117753A (ko) 항종양제로서의 ｃ21-데옥시 안사마이신 유도체
EP2079700A1 (en) 18, 21-didesoxymacbecin derivatives for the treatment of cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090520